
Oaktree Acquisition Corp. III Life Sciences
41
No recent business developments or news have been reported for Oaktree Acquisition Corp. III Life Sciences.
- No recent news or business developments have been reported for the company as of the latest filings [S1][S2].
Oaktree Acquisition Corp. III Life Sciences operates as a special purpose acquisition company (SPAC) targeting the life sciences industry. As a SPAC, its primary business model involves raising capital through an initial public offering to acquire or merge with an existing company in the life sciences sector. The company’s financial disclosures are limited, with no reported revenue or earnings, reflecting its status as a blank check company prior to completing a business combination.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Oaktree Acquisition Corp. III Life Sciences is a special purpose acquisition company (SPAC) focused on the life sciences sector. The latest SEC filings show limited financial data primarily related to liquidity and net loss, with no disclosed revenue or operational metrics. The company reported cash and equivalents of approximately $1.2 million and current liabilities of approximately $3.8 million as of September 30, 2026, resulting in a current ratio of 0.32. No recent business developments or news have been reported.
The company’s potential lies in successfully identifying and completing a business combination with a promising life sciences company, leveraging Oaktree’s investment expertise. Access to capital and a focused acquisition strategy could enable entry into a high-growth sector.
Risks include the inability to complete a suitable business combination within the required timeframe, liquidity constraints given the low current ratio, and the inherent uncertainties of SPAC structures. The absence of operational revenues and ongoing net losses highlight execution risks and financial sustainability concerns.
The company’s moat is primarily derived from its affiliation with Oaktree Capital Management and its focus on the life sciences sector, which may provide access to specialized acquisition targets. However, as a SPAC without an operating business, it currently lacks intrinsic competitive advantages or operational scale.
• Liquidity Risk: The company’s current ratio of 0.32 as of September 30, 2026, indicates limited short-term liquidity to cover current liabilities, which may constrain operational flexibility.
• Execution Risk: As a SPAC, the company faces the risk of not completing a business combination within the mandated timeframe, which could lead to liquidation or loss of shareholder value.
• Market and Sector Risk: Focusing on the life sciences sector exposes the company to sector-specific regulatory, technological, and market risks that could impact the attractiveness of acquisition targets.
Business trends: The company remains focused on identifying a life sciences acquisition target as a SPAC with no operational revenues.
Execution milestones: Completion of a business combination within the regulatory timeframe is critical.
Key risks: Liquidity constraints and the risk of failing to consummate a business combination pose significant challenges.
Moderate visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Oaktree Acquisition Corp. III Life Sciences is a special purpose acquisition company (SPAC) focused on the life sciences sector.
- As of September 30, 2026, the company reported cash and cash equivalents of $1,225,603 and current assets of $1,246,853.
- Current liabilities as of September 30, 2026, were $3,847,951, resulting in a current ratio of 0.32 and a cash ratio of 0.32, indicating liquidity constraints.
- The company reported a net loss of $452,553 for the quarter ending September 30, 2026.
- No revenue, earnings per share, or other operational financial metrics were disclosed in the latest filings.
- The latest financial data is sourced from the company's 10-Q filed on November 13, 2026, covering the quarter ended September 30, 2026.
- No recent business news or developments have been reported.
- The company’s filings include a 10-K annual report filed on March 26, 2026, and a 10-Q quarterly report filed on November 13, 2026.
Generated 2026-11-14
- S1 | 2026-03-26 | 10-K
- S2 | 2026-11-13 | 10-Q
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


